Literature DB >> 33012280

Methicillin-resistant Staphylococcus aureus: epidemiology and antimicrobial susceptibility experiences from the University Hospital 'Luigi Vanvitelli' of Naples.

D Pignataro1, F Foglia2, M T Della Rocca1, C Melardo1, B Santella1, V Folliero2, S Shinde2, P C Pafundi3, F C Sasso3, M R Iovene1, M Galdiero1,2, G Boccia4, G Franci4, E Finamore1, M Galdiero1,2.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the important pathogens worldwide showing resistance to several widely used antibiotics. This has made the treatment of MRSA infections harder, especially due to their prevalence in the hospital setting. We evaluated the antibiotic susceptibility patterns of healthcare-associated MRSA infections with a focus on Vancomycin Intermediate S. Aureus (VISA) and macrolide-licosamide-streptogramin B (MLSB) phenotypes. A total of 417 Staphylococcus aureus (S. aureus) cases were isolated between January 2017 and December 2018, through several clinical specimens collected from the University Hospital 'Luigi Vanvitelli' of Naples. We identified bacterial strains using Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) and antimicrobial susceptibility using Phoenix BD (Becton Dickinson, NJ, USA). Out of the total 417 S. aureus cases, 140 were MRSA (33.6%) and of these, 50% were soft tissue infections. All MRSA and Methicillin sensible S.aureus MSSA isolates were susceptible to linezolid and daptomycin. Two MRSA cases exhibited intermediate resistance to vancomycin and were of constitutive MLSB phenotype. Among the MRSA strains, 11.4% were constitutive and 43.6% were inducible MLSB phenotypes and 8.6% were macrolide-streptogramin B phenotype. This study characterized the epidemiological status, antibiotic resistance patterns, and current prevalent phenotypes of healthcare-associated MRSA. This knowledge can aid clinicians in improving the antimicrobial stewardship program by adapting appropriate guidelines for the proper use of MRSA antibacterial agents.

Entities:  

Keywords:  MLSB phenotypes; Methicillin-resistant Staphylococcus aureus ; antibiotic susceptibility patterns; healthcare infections; vancomycin

Mesh:

Substances:

Year:  2020        PMID: 33012280      PMCID: PMC7831655          DOI: 10.1080/20477724.2020.1827197

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  33 in total

1.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus.

Authors:  Christine D Steward; Patti M Raney; Allison K Morrell; Portia P Williams; Linda K McDougal; Laura Jevitt; John E McGowan; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

Review 4.  The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors:  K Hiramatsu; L Cui; M Kuroda; T Ito
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

5.  An outbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection in dermatology indoor patients.

Authors:  D Sachdev; S Amladi; G Natraj; S Baveja; V Kharkar; S Mahajan; U Khopkar
Journal:  Indian J Dermatol Venereol Leprol       Date:  2003 Nov-Dec       Impact factor: 2.545

Review 6.  Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.

Authors:  Frank R DeLeo; Henry F Chambers
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

Review 7.  Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  Sirijan Santajit; Nitaya Indrawattana
Journal:  Biomed Res Int       Date:  2016-05-05       Impact factor: 3.411

Review 8.  Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.

Authors:  Mansura S Mulani; Ekta E Kamble; Shital N Kumkar; Madhumita S Tawre; Karishma R Pardesi
Journal:  Front Microbiol       Date:  2019-04-01       Impact factor: 5.640

Review 9.  Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus.

Authors:  Yunlei Guo; Guanghui Song; Meiling Sun; Juan Wang; Yi Wang
Journal:  Front Cell Infect Microbiol       Date:  2020-03-17       Impact factor: 5.293

10.  Molecular Typing and Antimicrobial Susceptibility of Methicillin-Resistant Staphylococcus aureus Isolated from Bovine Milk in Tanzania.

Authors:  Jibril Mohammed; Michael Henry Ziwa; Yaovi Mahuton Gildas Hounmanou; Adela Kisanga; Huruma Nelwike Tuntufye
Journal:  Int J Microbiol       Date:  2018-03-12
View more
  2 in total

1.  Grape Canes from Typical Cultivars of Campania (Southern Italy) as a Source of High-Value Bioactive Compounds: Phenolic Profile, Antioxidant and Antimicrobial Activities.

Authors:  Giuseppe Squillaci; Carla Zannella; Virginia Carbone; Paola Minasi; Veronica Folliero; Debora Stelitano; Francesco La Cara; Massimiliano Galdiero; Gianluigi Franci; Alessandra Morana
Journal:  Molecules       Date:  2021-05-07       Impact factor: 4.411

2.  Postmortem interval assessment by MALDI-TOF mass spectrometry analysis in murine cadavers.

Authors:  Federica Dell'Annunziata; Francesca Martora; Maria Elena Della Pepa; Veronica Folliero; Livio Luongo; Serena Bocelli; Francesca Guida; Pasquale Mascolo; Carlo Pietro Campobasso; Sabatino Maione; Gianluigi Franci; Marilena Galdiero
Journal:  J Appl Microbiol       Date:  2021-08-08       Impact factor: 4.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.